167 related articles for article (PubMed ID: 12504803)
1. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Crul M; van Waardenburg RC; Bocxe S; van Eijndhoven MA; Pluim D; Beijnen JH; Schellens JH
Biochem Pharmacol; 2003 Jan; 65(2):275-82. PubMed ID: 12504803
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Moufarij MA; Phillips DR; Cullinane C
Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
[TBL] [Abstract][Full Text] [Related]
3. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.
Besançon OG; Tytgat GA; Meinsma R; Leen R; Hoebink J; Kalayda GV; Jaehde U; Caron HN; van Kuilenburg AB
Cancer Lett; 2012 Jun; 319(1):23-30. PubMed ID: 22182450
[TBL] [Abstract][Full Text] [Related]
5. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil.
Haveman J; Castro Kreder N; Rodermond HM; van Bree C; Franken NA; Stalpers LJ; Zdzienicka MZ; Peters GJ
Oncol Rep; 2004 Jul; 12(1):187-92. PubMed ID: 15201982
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of homologous DNA recombination repair by gemcitabine.
Wachters FM; van Putten JW; Maring JG; Zdzienicka MZ; Groen HJ; Kampinga HH
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):553-62. PubMed ID: 12957269
[TBL] [Abstract][Full Text] [Related]
9. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Alli E; Sharma VB; Hartman AR; Lin PS; McPherson L; Ford JM
BMC Pharmacol; 2011 Jul; 11():7. PubMed ID: 21771338
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.
Lee KB; Parker RJ; Bohr V; Cornelison T; Reed E
Carcinogenesis; 1993 Oct; 14(10):2177-80. PubMed ID: 8222071
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
12. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.
Spencer DM; Bilardi RA; Koch TH; Post GC; Nafie JW; Kimura K; Cutts SM; Phillips DR
Mutat Res; 2008 Feb; 638(1-2):110-21. PubMed ID: 17961607
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
14. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of adaptive responses to cisplatin in normal and mutant cell lines with mutations in recombination repair pathways.
Raaphorst GP; Li LF; Yang DP
Anticancer Res; 2006; 26(2A):1183-7. PubMed ID: 16619522
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
17. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts.
Malina J; Kasparkova J; Natile G; Brabec V
Chem Biol; 2002 May; 9(5):629-38. PubMed ID: 12031669
[TBL] [Abstract][Full Text] [Related]
18. Preclinical perspectives on platinum resistance.
Kelland LR
Drugs; 2000; 59 Suppl 4():1-8; discussion 37-8. PubMed ID: 10864225
[TBL] [Abstract][Full Text] [Related]
19. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
[TBL] [Abstract][Full Text] [Related]
20. Chromium(VI) enhances (+/-)-anti-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-induced cytotoxicity and mutagenicity in mammalian cells through its inhibitory effect on nucleotide excision repair.
Hu W; Feng Z; Tang MS
Biochemistry; 2004 Nov; 43(44):14282-9. PubMed ID: 15518579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
